BioCentury | Apr 19, 2019
Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

...Inc. (Cambridge, Mass.), which on Thursday named Paul Wotton CEO. The company formerly known as Regenerex LLC...
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex LLC...
...of Louisville and later developed by Novartis AG (NYSE:NVS; SIX:NOVN) under a 2013 deal with Regenerex...
...Gornstein was senior director, insights and analytics at Radius Health Inc. (NASDAQ:RDUS). Chris Lieu, Staff Writer Novartis AG Regenerex LLC FCR001 Talaris...
BioCentury | Nov 11, 2013
Company News

Regenerex, Novartis, University of Louisville deal

...and royalty payments from Regenerex as part of a September deal between Regenerex and Novartis. Regenerex...
...with Novartis for the biotech's hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) technology, to which Regenerex...
...graft survival without the need for immunosuppression. The university could not be reached for details. Regenerex LLC...
BioCentury | Sep 16, 2013
Company News

Regenerex, Novartis deal

...Regenerex granted Novartis exclusive, worldwide rights and entered a research collaboration deal for Regenerex's hematopoietic stem...
...for use in inherited metabolic storage disorders and hemoglobinopathies. Novartis declined to disclose details, and Regenerex...
...which consists of a cancer antigen-binding domain targeting CD19 linked to CD3-zeta/CD137 immunostimulatory domains. Regenerex LLC...
Items per page:
1 - 4 of 4
BioCentury | Apr 19, 2019
Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

...Inc. (Cambridge, Mass.), which on Thursday named Paul Wotton CEO. The company formerly known as Regenerex LLC...
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex LLC...
...of Louisville and later developed by Novartis AG (NYSE:NVS; SIX:NOVN) under a 2013 deal with Regenerex...
...Gornstein was senior director, insights and analytics at Radius Health Inc. (NASDAQ:RDUS). Chris Lieu, Staff Writer Novartis AG Regenerex LLC FCR001 Talaris...
BioCentury | Nov 11, 2013
Company News

Regenerex, Novartis, University of Louisville deal

...and royalty payments from Regenerex as part of a September deal between Regenerex and Novartis. Regenerex...
...with Novartis for the biotech's hematopoietic stem cell-based Facilitating Cell Therapy (FCRx) technology, to which Regenerex...
...graft survival without the need for immunosuppression. The university could not be reached for details. Regenerex LLC...
BioCentury | Sep 16, 2013
Company News

Regenerex, Novartis deal

...Regenerex granted Novartis exclusive, worldwide rights and entered a research collaboration deal for Regenerex's hematopoietic stem...
...for use in inherited metabolic storage disorders and hemoglobinopathies. Novartis declined to disclose details, and Regenerex...
...which consists of a cancer antigen-binding domain targeting CD19 linked to CD3-zeta/CD137 immunostimulatory domains. Regenerex LLC...
Items per page:
1 - 4 of 4